Vankayalapati, Hariprasad et al. published their patent in 2012 |CAS: 1186608-73-0

The Article related to pyrazinylpyrazolopyridine pyrazolopyridine preparation protein kinase inhibitor antitumor antiinflammatory antiparkinsonian, parkinson’s alzheimer’s disease down’s syndrome treatment pyrazinylpyrazolopyridine pyrazolopyridine preparation, huntington’s disease neurodegenerative cns disorder treatment pyrazinylpyrazolopyridine pyrazolopyridine preparation and other aspects.COA of Formula: C7H8N4

On October 4, 2012, Vankayalapati, Hariprasad; Appalaneni, Rajendra P.; Reddy, Y. Venkata Krishna published a patent.COA of Formula: C7H8N4 The title of the patent was Preparation of substituted 5-(pyrazin-2-yl)-1H-pyrazolo[3,4-b]pyridine and pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors. And the patent contained the following:

This invention relates to the title compounds I-III [X = N, CH; L1 = a bond, (un)substituted 6-membered aryl, heteroaryl, etc.; R1-R3 = H, halo, CN, etc.; Q = NH, O, S, etc.; L2 = IV (wherein X1 = N, CH; X2 = N, CH; X3 = N, CH; R10 = H, halo, CN, etc.)] which are inhibitors of constitutively activated Tyrosine Kinase-Like (TKL), CMGC protein kinases family members and can be useful in the treatment of Parkinson’s disease, Alzheimer’s disease, Down’s syndrome, Huntington’s disease, other neurodegenerative and central nervous system disorders, cancer, metabolic disorders and inflammatory diseases, and to methods for making them. Seventy title compounds were prepared and formulated. For example, a multi-step synthesis of V, starting from mucobromic acid, was described. Exemplified title compounds were tested in the LRRK2 kinase assay (data given). Also disclosed are pharmaceutical compositions including the title compounds and methods of inhibiting wild type and/or mutated protein kinase activities of these families and the treatment of disorders associated therewith using title compounds and pharmaceutical compositions including the title compounds The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).COA of Formula: C7H8N4

The Article related to pyrazinylpyrazolopyridine pyrazolopyridine preparation protein kinase inhibitor antitumor antiinflammatory antiparkinsonian, parkinson’s alzheimer’s disease down’s syndrome treatment pyrazinylpyrazolopyridine pyrazolopyridine preparation, huntington’s disease neurodegenerative cns disorder treatment pyrazinylpyrazolopyridine pyrazolopyridine preparation and other aspects.COA of Formula: C7H8N4

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics